Skip to main content

Table 2 Summary of Best Overall Response (CR + PR) by Study Treatment (Assessed by Committee)

From: Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

Evaluable patients

17

Complete Response

0

Partial Response

0

Stable Disease

12

Disease Progression

4

Not Evaluable

1

Overall Response Rate

0

Disease Control Rate

70.6 %

  1. Evaluable Patients: The full analysis set (FAS) of 17 includes patients who received at least one dose of TP300 and had at least one measurable target-lesion confirmed by independent review committee (IRC)
  2. Not Evaluable: 1 patient did not have a post dose tumour radiological assessment, so could not be assessed
  3. Note: A further 2 patients who received TP300 were excluded from the FAS, as the target lesion/s could not be confirmed by IRC